700 women followed for over a decade to see which fibroid treatments last longest

NCT ID NCT06430320

Ongoing Knowledge-focused Sponsor: Henry Ford Health System Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows about 700 women for up to 12 years after they had a uterine-sparing fibroid treatment, such as myomectomy or uterine artery embolization. Researchers want to see how long these treatments last before another procedure is needed, and how women's symptoms and quality of life change over time. Participants were previously enrolled in the COMPARE-UF or ULTRA studies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this study could help doctors and patients choose the best fibroid treatment by showing which ones last longest without needing another procedure.
What could go wrong: This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results depend on participants accurately reporting their health over many years.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for UTERINE FIBROID are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

leiomyoma uterine corpus leiomyoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

UTERINE FIBROID

Contacts and locations

Locations

Henry Ford Health

Detroit, Michigan, 48202, United States
Mayo Clinic

Rochester, Minnesota, 55905, United States
The University of North Carolina at Chapel Hill

Chapel Hill, North Carolina, 27514, United States
University of California San Francisco

San Francisco, California, 94143, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.